News

Overview

Press Release
img

2019/11/29

WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products

Shanghai and Seoul, November 29, 2019 - WuXi ATU Co., Ltd., (WuXi ATU) - a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the development and manufacturing of oncolytic virus products. Under the terms of the collaboration, WuXi ATU will provide overall process development, manufacturing and Investigational New Drug (IND) filing services for GeneMedicine’s oncolytic virus products.

2019/11/18

WuXi AppTec's Lab Testing Division Expands Toxicology Facility in Suzhou, China

SHANGHAI, Nov. 18, 2019 - WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced its Lab Testing Division (LTD) has expanded the Suzhou safety assessment facility by increasing toxicology capacity by 80% to meet global customers’ preclinical testing needs and enable them to accelerate the development timelines and bring innovative medicines to patients faster.

2019/11/15

WuXi AppTec Receives 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan

SHANGHAI, Nov. 15, 2019 -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a global business research and consulting firm. WuXi AppTec was awarded this honor for the third consecutive year.

Media Center

Provide WuXi at a glance, media package and company photos for media to download

Upcoming Events

Discover WuXi AppTec Conference and Event Information